Bone-biomarkers of Spinal Cord Injury Patients

  • STATUS
    Recruiting
  • participants needed
    64
  • sponsor
    Yeungnam University Hospital
Send
Updated on 16 February 2024
See if I qualify
injuries
osteoporosis
romosozumab
spinal cord injury
sclerostin
spinal cord disorder
sclerostin inhibitor

Summary

Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed. In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high therapeutic effect as an inhibitor of bone resorption while promoting bone formation. However, there are a few research concerning sclerostin of spinal cord injuries patients. Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.

Details
Condition Osteopenia, Osteopenia, Spinal Cord Injury, Myelopathy, spinal cord disorders, Trauma, wounds, Osteoporosis, Osteoporosis, Bone Diseases, Bone Diseases, Bone Resorption, wounds, spinal cord disorders
Age 20years - 100years
Clinical Study IdentifierNCT04403256
SponsorYeungnam University Hospital
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

spinal cord injury patients
Functional ambulatory category index of 3 or less

Exclusion Criteria

history of using bone absorption medication within the effective period
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

injuries
osteoporosis
romosozumab
spinal cord injury
sclerostin
spinal cord disorder
sclerostin inhibitor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.